Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme - IL-17 antagonist - DICE Therapeutics

Next Previous
X
Search
Drug Profile

Research programme - IL-17 antagonist - DICE Therapeutics

Alternative Names: IL-17 antagonist-DICE-Therapeutics; Novel scaffold program #1 (Fast follower); Novel scaffold program #2

Latest Information Update: 11 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DiCE Molecules
  • Developer DICE Therapeutics
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Interleukin 17 receptor antagonists; Protein-protein interaction inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Immunological disorders; Psoriasis

Most Recent Events

  • 09 Aug 2023 DICE Therapeutics has been acquired by Eli Lilly and Company
  • 19 Oct 2021 Preclinical trials in Immunological disorders in USA (PO) befor October 2021 (DICE Therapeutics pipeline, October 2021)
  • 08 Jan 2021 Preclinical trials in Psoriasis in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top